A Phase I, Partially-randomised, Partially Double-blinded, Safety, Tolerability and Pharmacokinetic Study of ABY-035 in Healthy Subjects and Psoriasis Patients

Trial Profile

A Phase I, Partially-randomised, Partially Double-blinded, Safety, Tolerability and Pharmacokinetic Study of ABY-035 in Healthy Subjects and Psoriasis Patients

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs ABY 035 (Primary) ; ABY 035 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; First in man
  • Sponsors Affibody
  • Most Recent Events

    • 01 Nov 2017 Planned number of patients changed from 64 to 76.
    • 01 Nov 2017 Planned End Date changed from 1 Mar 2017 to 1 Jan 2018.
    • 01 Nov 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top